Since sorafenib is known to induce apoptosis in HCC, we investigated the influence of sorafenib and of FB1 and SPHK inhibitors on the proliferation of HepG2 and Huh7.5 cells. This evidence concerns the gene SPHK1 and hepatocellular carcinoma.